Introduction
Disorders of lipoprotein metabolism lead to atherosclerosis and cardiovascular disease (CVD), including myocardial infarction and stroke. Sixteen million adults in the United States alone live with coronary artery disease, which kills 450 000 people annually [1] . Because of the well established relationship between serum lipid levels and CVD, serum lipids have long been of clinical interest. In particular, low-density lipoprotein cholesterol (LDL-C) is recognized not only as a biomarker of CVD risk, but also as a causal participant in the disease process.
Serum lipid levels, including LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides are highly heritable: studies consistently estimate that over 50% of the total interindividual variation in serum lipid levels can be explained by the genetic variation [2] . Therefore, there is substantial interest in discovering the genetic determinants of lipid levels, particularly genes that alter both serum lipids and CVD risk.
Mendelian lipoprotein disorders
Most of the well characterized disorders of lipoprotein metabolism are monogenic, familial disorders with extreme phenotypes amenable to linkage analysis. For example, proprotein convertase subtilisin/kexin type 9 (PCKS9) has recently been implicated in a form of autosomal-dominant hypercholesterolemia (ADH). Its protein product normally associates with hepatic and extrahepatic LDL receptors and appears to target them for endosomal degradation [3] . Gain-of-function variants (such as D374Y) lead to a 10-fold reduction in LDL receptor levels, causing increased LDL-C levels and resulting in ADH [4, 5] .
Various Mendelian disorders of lipoprotein metabolism have now been described for each of the three lipoprotein traits, and up to now they have contributed the bulk of our knowledge about lipoprotein genetics [6] . Although those who harbor such traits experience profound phenotypes, the population-wide impact of the known Mendelian disorders is attenuated by their rarity. The monogenic lipid disorders discovered thus far can explain little of overall lipoprotein heritability. Indeed, the normal distribution of serum lipoprotein levels in the population suggests a polygenic model of inheritance: LDL-C, HDL-C, and triglyceride levels are determined by the additive contribution of multiple loci.
Common variants
In contrast to the linkage studies that were well suited to identifying rare variants with profound effects, genomewide association (GWA) studies have been designed to ascertain whether common genetic variants contribute to population-wide lipid variability. In such studies, hundreds of thousands of single-nucleotide polymorphisms (SNPs) are interrogated for association with serum
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Each GWA study has shared similar approaches. Hundreds of thousands of SNPs are genotyped in a discovery cohort, with follow-up genotyping performed on a subset of those SNPs in a replication cohort. With linear regression, each allele is correlated to the serum level of each lipoprotein trait. Only genetic loci passing genome-wide significance (P < 5 Â 10 À8 ) are reported; the success of this stringent criterion in minimizing false associations is underscored by the fact that, in each successively larger GWA study, no previously significant loci have dropped from significance.
The first large-scale lipids GWA study, published in 2007, involved 2800 individuals genotyped at nearly 400 000 SNPs [7] . This study re-discovered associations known from prior genetic studies: that of HDL-C with cholesteryl ester transfer protein (CETP), and of LDL-C with apolipoprotein E (APOE), which effectively served as positive controls that confirmed GWA as a valid approach to identifying lipid-associated loci. Progressively larger studies have been conducted; the most recent lipids GWA studies from 2009 involved up to 40 000 individuals of European descent and identified more than 30 chromosomal loci with common variants associated with lipid levels [8 ,9 ] . An in-progress study by the Global Lipids Genetics Consortium involving over 100 000 individuals will likely identify still more loci.
The lipids GWA studies have led to the observation that genes with rare Mendelian mutations of large effect size also harbor common variants of more modest effect sizes [8 ,9 ] (Table 1 ). These findings prompt the reciprocal hypothesis: many lipid-associated loci mapped using common variants will also harbor novel low-frequency (1-5% frequency) and rare (<1% frequency) variants with more pronounced effects. 
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HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides. Adapted from [8 ] .
Already 30 common lipid-associated variants have explained 9.3, 7.7, and 7.4% of interindividual variability for HDL-C, LDL-C, and triglycerides, respectively [8 ] . These variants, therefore, explain approximately 15-18% of heritability -a proportion that likely will increase with publication of the 100 000-individual lipids GWA study. Much of the remaining heritability may ultimately be attributable to low-frequency and rare variants.
Next steps after genetic mapping using common variants GWA has provided a flood of common genetic variants that are strongly associated with lipoprotein levels and have begun to explain substantial fractions of heritability.
The tasks now at hand are to narrow the scope of localization from the chromosomal region to the level of the functional element (gene or regulatory element) and to explain the molecular mechanisms that ultimately lead to the observed lipid phenotypes. DNA sequencing and functional biology will be instrumental to these ends.
Sequencing
Sequencing offers the promise of identifying the variants driving the GWA signals. Because of the underlying patterns of linkage disequilibrium, a GWA SNP may only narrow the search to a several-hundred-kilobase region. Targeted, large-scale sequencing in unrelated individuals should ascertain all of the variants in the region and, therefore, reduce the scope of the functional search down to a focused assortment of dozens of specific variants, one or more of which is likely to have functional consequences.
In some cases, sequencing may even identify smokinggun variants, such as early truncations, that strongly indicate causation. Studies of PCSK9 are suggestive in this regard. The gene harbors a common variant (19% minor allele frequency) identified in a 40 000-person lipids GWA study [10] . PCSK9 has also been shown to contain low-frequency nonsense variants that lead to a 15-28% reduction in LDL-C and a 47-88% decrease in lifetime risk of CVD [5] . Additionally, the rare gain-offunction variants, discussed above, implicate PCSK9 in a form of ADH. If this pattern of common, low-frequency, and rare variants being present at a lipid locus is typical, then sequencing near GWA loci may identify not only the source of the GWA hit, but also a trove of causal lowfrequency and rare variants. Nevertheless, even variants that appear likely to be causal (truncations, nonconservative substitutions) will require functional validation.
As the efficiency of sequencing increases and the cost falls, targeted sequencing will give way to whole-exome sequencing, and, in turn, to whole-genome sequencing -far exceeding the association boundaries of the regions initially highlighted by GWA studies. Such enhancement of our catalogue of lipid variants by sequencing may also prove fruitful for improved risk prediction and for the identification of a set of genes enriched for plausible pharmacological targets.
Functional validation
GWA and deep resequencing are highly informative, but fall short of elucidating a functional link between DNA sequence variant and lipoprotein phenotype. To provide convincing evidence of causality, functional studies will be required. Many GWA-identified loci are in linkage disequilibrium blocks spanning one or more genes; such loci immediately suggest protein targets to interrogate, whether through animal models, molecular biology, or emerging techniques. More difficult to study will be the loci that harbor no known genes, though many will ultimately be discovered to harbor regulatory elements important for modulating the expression of genes in lipoprotein metabolic pathways.
Ultimately, the fulfillment of genetic Koch's postulates would provide the most convincing evidence of causality, requiring identification of the SNP that, presumptively, causes variation in a lipid trait; development of a valid model such as that from induced pluripotent stem cells (iPS) from individuals with and without the variant; highly targeted manipulation of the DNA to replace the common allele with the variant; and observation of a change in phenotype consistent with the proposed directionality and degree of variation (i.e., substituting the variant allele for the common allele and observing a phenotype consistent with that found in those natively harboring the variant allele). Such an approach would be particularly useful in confirming the causality of variants that appear to reside in intergenic 'deserts.'
Clinical applications
In parallel to the work being done on elucidating the biology underlying the GWA signals, efforts are underway to take advantage of the presently available data for clinical risk prediction and personalized pharmacology.
Genetic risk stratification
There are advantageous theoretical properties to a genetic screen for plasma lipoproteins. Genetic scores are immutable within an individual, which may reduce costs due to decreased repeat testing and allow for very early detection of individuals at increased risk for CVD. Such scores may better represent the cumulative lifetime burden of exposure to lipids than point estimates of fasting lipid levels [11] .
Because CVD is the ultimate outcome of interest, not lipoprotein levels per se, genetic screens may be particularly helpful if not all causes of lipid variation confer equal CVD risk (for example, if certain causes of increased HDL-C are protective, whereas others are not). Such a possibility was brought to the fore by the failure of torcetrapib, the CETP inhibitor, to reduce cardiovascular mortality or intermediate endpoints, despite increasing HDL (though this result should not be overinterpreted, as torcetrapib has molecule-specific off-target effects that trigger mineralocorticoid excess) [12] [13] [14] . On the other hand, persons with null mutations in APOC3 experience increased HDL-C, reduced triglyceride, and a reduction in coronary calcification [15 ] . This suggests that not all causes of elevated HDL-C carry the same consequences for CVD. Specific variants contributing to the observed serum lipoprotein levels may convey substantial information beyond that encoded by the scalar lipid levels themselves.
Nevertheless, genetic scores have not proven superior to lipoprotein levels and family history for CVD risk discrimination. For example, the use of one risk allele in the well known 9p21 locus in white women did not improve discrimination or reclassification beyond that achievable using serum lipids, C-reactive protein (CRP), and family history [16 ] . In contrast, we have demonstrated a lipid genetic panel using SNPs identified in the pre-GWA era; the panel did not improve risk discrimination but did improve risk reclassification [11] . As more variants are identified through GWA studies and sequencing, expanded panels will be developed that may achieve the goal of improved discrimination. At that point, the clinical utility of such panels should be examined in the context of a clinical trial.
Pharmacogenetics
Whereas genetic risk profiling is used to rule in those who would ordinarily not be considered for therapy, pharmacogenetics may be used to exclude patients from what would otherwise be the default treatment. Here we will split the subject of lipid pharmacogenetics into two topics: efficacy-oriented pharmacogenetics and toxicityoriented pharmacogenetics.
Trials have now demonstrated proof-of-principle for efficacy-oriented pharmacogenetic approaches to predicting statin response [17 ,18 ] . For example, the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) Thrombolysis in Myocardial Infarction (TIMI) 22 trial examined the effect of SNPs from genes in LDL-C metabolism pathways and statin pharmacokinetics pathways on the response to atorvastatin or pravastatin [17 ] .
Carriers with APOE isoform e2 demonstrated greater reduction in LDL-C than did e4 carriers and were more likely to reach target LDL-C levels [17 ] . In this study, APOE isoforms explained 3.8% of the residual variance in response to statin therapy. Nevertheless, statin therapy can already be titrated based on lipid levels at follow-up. Perhaps a pharmacogenetic panel could be built to address whether a failure to reduce LDL-C despite statin therapy was due to nonadherence or, instead, to genetically encoded resistance, but the clinical utility of such a tool is unclear. Efficacy-oriented pharmacogenetic approaches are unlikely to be clinically compelling in the absence of a trial that demonstrates that an interaction between statin choice and genotype can lead to differential outcomes, even after controlling for lipoprotein levels. . This study showed that the use of genetic information for cardiovascular risk prediction did not offer any advantage over the use of serum lipids, CRP, and family history. This study found that 60% of simvastatin-induced myopathy could be attributed to a variant in SLCO1B1, which encodes the organic anion transporter OATP1B1 that is responsible for the hepatic uptake of most statins. This study found that the effect of SLCO1B1 variants did not signify the same risk of adverse events for all statins.
